Quidel Corp.

Description

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC women's and general health, and gastrointestinal diseases. The company offers Sofia influenza A+B and QuickVue influenza tests to detect viral antigens of influenza type A and B; Sofia strep A fluorescent immunoassay and QuickVue Strep A tests to detect group A Streptococcal antigen from throat swabs; and Sofia Respiratory Syncytial Virus (RSV), QuickVue RSV, and Quidel Molecular RSV + human metapneumovirus tests for respiratory syncytial virus. It also provides various products to detect various herpes simplex virus (HSV) and herpes family viruses; H&V-Mix to isolate HSV, VZV, and Cytomegalovirus; R-Mix to detect Influenza A and B, RSV, Adenovirus, and Parainfluenza types 1, 2, and 3; Sofia S. Pneomoniae fluorescent immunoassay (FIA) to detect pneumococcal pneumonia and meningitis; Sofia Legionella FIA to detect Legionella pneumophila seorgroup 1 antigen; AmpliVue Bordetella assay to detect Bordetella pertussis; and Lyra Adenovirus assay to detect human adenovirus viral DNA. In addition, the company offers Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests to detect hCG in serum or urine; Thyretain for the diagnosis of graves disease; QuickVue Chlamydia test to detect Chlamydia trachomatis; Solana Trichomonas assay for the diagnosis of trichomoniasis; and clinical and research products for the assessment of osteoporosis and evaluation of bone resorption/formation. Further, it provides Lyra Direct C. difficile assay to detect Clostridium difficile Toxin A or Toxin B genes; Super E-Mix and D3 IFA Enterovirus indirect fluorescent antibody products; QuickVue fecal immunochemical test to detect the presence of blood in stool specimens; and serological tests to measure antibodies circulating in the blood. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.